Sino Biopharmaceutical Limited
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sino Biopharmaceutical Limited
Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.
As demand for Wegovy busts through capacity, Biogen’s Viehbacher asks if we need to spend on drugs for weight loss or other preventable diseases when the dollar could go towards non-preventable chronic diseases. Discussing investments at a recent conference, he was joined by Fidelity’s Rajiv Kaul who said the concept of therapeutic classes is outdated
Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.
Sino Biopharm's $161m all-cash acquisition of F-star has finally closed amid heightening US-China tensions and following completion the Chinese firm, through its UK subsidiary invoX, plans to expand its operations and presence at F-star’s UK headquarters.
- Drug Delivery
- Generic Drugs
Drug Discovery Technologies
- Natural Products
- Molecular Diversity
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Beijing Tide Pharmaceutical Co Ltd, invoX Pharma
- Jiangsu Chia Tai Tianqing Pharmaceutical Co Ltd, Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd, Qingdao Chia Tai Haier Pharmaceutical Co Ltd, Jiangsu Chia Tai Qing Jiang Pharmaceutical Co Ltd, etc. Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.